Agree, I just doubt that current Gen1,2,3 would be suitable unless tailored to pass the bbb 👍🏻
1
1
202
Replying to @SeanDentBsc @avacta
I know the blood brain barrier could provide stiff challenge for Avacta. Unfortunately my dad is at the end of his 18month life expectancy suffering with a grade 4 glioblastoma. I was rather hoping there would be a trial for GB in truth.
Sincerely hope it works for others sake ❤️
Replying to @tom_the_bomb__
Suprised me that some are not. Assuming they are big co’s.
Ultimately I trust the board to extract value and the tech is looking more and more solid everyday, however the frustration is real 😆/😩
1
190
Replying to @Cumulus51896691 @TonyRob70579912
Agree. I remember years ago discussing with shareholders how we had concerns FAP ‘could’ reduce during treatment putting the Med/Long term use of the platform at risk. Bizarrely no one ever suggested it would increase FAP…. And yet here we are. Fantastic! #avct
This is the best part of the RNS
#avct ❤️🥇 incredible:
‘Tumor tissue studies from this experiment demonstrate that tumors treated with AVA6103 have increased FAP expression over time via immunohistochemistry, with recruitment of FAP+ fibroblasts over the course of treatment
1/2
Replying to @AndrewDigby3
Personally removed any hope of the SP moving significantly until p1 efficacy data is released followed by some form of deal. Anything else is a bonus.
👍🏻
*6000 feels ‘side of desk’ with 6103 performing (maybe rightly so).
Potentially BP feel the same.
*this time next year Rodney 👏🏻
Happy investor. SP is an opportunity, but must raise significantly through next year or unanswered commercial Q’s will be brought to a head
4/4 #avct
My thoughts:
*CC was excellent again. Discussing complexity with clarity & terminology that was absorbing for all.
*confidence was high. 6103 readout being a close match to pre-clinical was the standout moment of the presentation for me. They must be seeing efficacy
1/4 #avct
Replying to @ZosoGraffiti
We will see… I sure hope so. I just feel like the tide is turning away from 6k all together, which I guess is positive because that’s due to the excitement around 6103. Fingers crossed they get it partnered soon to enable P2 & a much anticipated BP commercial deal
1
2
83
Replying to @massivefanNWO
No doubt it’s nice to see. I’m pleased they have done so & that does offer some confidence. But ‘tremendous confidence’?
I’d be reserving that for II’s coming on board, raising at a premium, BP wanting a slice…. Etc.
Replying to @ZosoGraffiti
Agree, but I’m starting to think 6k will get superseded very quickly, therefore reducing profitability for a partner. This being my reasoning for 6k deals being v-low value.
2
3
133
Slept on it & still disappointed. #avct
Ben captures my thoughts well. A good post.
fear for 6k is that nobody wants to deal at any decent value, as a next gen dox would wipe the floor (capping +pre|C +linker +dox) 🤔
Feels like an all or nothing crescendo on 6103 efficacy
3
12
2,004
